Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity

References

• SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute; 2004.
   Google Scholar
• Appelbaum FR, Gundacker H, Head DR, . Age and acute myeloid leukemia. Blood 2006;107:3481–3485.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154–1163.
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Kayser S, . Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years:results from AMLSG trial AML HD98-B. Blood 2006;108:3280–3288.
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38–51.
   PubMed Web of Science ®Google Scholar
• Tang R, Faussat AM, Majdak P, . Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004;18:1246–1251.
   PubMed Web of Science ®Google Scholar
• Nebbioso A, Clarke N, Voltz E, . Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77–84.
   PubMed Web of Science ®Google Scholar
• Pilatrino C, Cilloni D, Messa E, . Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005;104:101–109.
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Schmid M, Schlenk R, . The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006;106:112–119.
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Strupp C, Aivado M, . Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266–1269.
   PubMed Web of Science ®Google Scholar
• Bellos F, Mahlknecht U. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologi 2008;31:629–633.
   PubMed Web of Science ®Google Scholar
• Siitonen T, Koistinen P, Savolainen ER. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells. Leuk Res 2005;29:1335–1342.
   PubMed Web of Science ®Google Scholar
• Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, . Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006;108:1174–1182.
   PubMed Web of Science ®Google Scholar
• Maggio SC, Rosato RR, Kramer LB, . The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 2004;64:2590–2600.
   PubMed Web of Science ®Google Scholar
• ten Cate B, Samplonius DF, Bijma T, . The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 2007;21:248–252.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, . Phase study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271–3279.
   PubMed Web of Science ®Google Scholar
• Spriggs D, Griffin J, Wisch J, . Clinical pharmacology of low-dose cytosine arabinoside. Blood 1985;65:1087–1089.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Moorman A, Hills R, . Impact of karyotype on treatment outcome in acute myeloid leukemia. Ann Hematol 2004;83(Suppl. 1):S45–S48.
   PubMedGoogle Scholar
• Cheson BD, Bennett JM, Kantarjian H, . Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671–3674.
   PubMed Web of Science ®Google Scholar
• Common Toxicity Criteria, Version 2.0. [Internet]. National Cancer Institute. 1998. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
   Google Scholar
• Xie C, Edwards H, Xu X, . Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 2010;16:5499–5510.
   PubMed Web of Science ®Google Scholar
• Tang R, Faussat A, Majdak P, . Valproic acid inhibits proliferation and induces apoptosis in acute myeloid meukemia cells expressing P-gp and MRP1. Leukemia 2004;18:1246–1251.
   PubMed Web of Science ®Google Scholar
• Giles F, Fischer T, Cortes J, . A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12:4628–4635.
   PubMed Web of Science ®Google Scholar
• Shiozawa K, Nakanishi T, Tan M, . Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res 2009;15:1698–1707.
   PubMed Web of Science ®Google Scholar
• Burnett A, Baccarani M, Johnson P, . Effectiveness of clofarabine in elderly AML patients with adverse cytogenetics unfit for intensive chemotherapy. Blood 2006;108(Suppl. 1): Abstract 1985.
   Google Scholar
• Corsetti MT, Salvi F, Perticone S, . Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. Leuk Res 2011;35:991–997.
   PubMed Web of Science ®Google Scholar
• Bug G, Ritter M, Wassmann B, . Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005;104:2717–2725.
   PubMed Web of Science ®Google Scholar
• Cimino G, Lo-Coco F, Fenu S, . Sequential valproic acid/ all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006;66:8903–8911.
   PubMed Web of Science ®Google Scholar
• Raffoux E, Chaibi P, Dombret H, . Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005;90:986–988.
   PubMed Web of Science ®Google Scholar
• Khanim FL, Bradbury CA, Arrazi J, . Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. Br J Haematol 2009;144:332–341.
   PubMed Web of Science ®Google Scholar
• Raffoux E, Cras A, Recher C, . Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010;1:34–42.
   PubMed Web of Science ®Google Scholar
• Soriano AO, Yang H, Faderl S, . Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302–2308.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, . Phase study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271–3279.
   PubMed Web of Science ®Google Scholar
• Blum W, Klisovic RB, Hackanson B, . Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884–3891.
   PubMed Web of Science ®Google Scholar